COVID-19 Mutation: BioNTech and Pfizer Talk About Vaccine Effectiveness



[ad_1]

COVID-19 Mutation: BioNTech and Pfizer Talk About Vaccine Effectiveness

Photo: news.24tv.ua

BioNTech / Pfizer vaccine could be effective against new COVID strain

Developers of the COVID vaccine will soon study in more detail the effect of the vaccine on the new strain of coronavirus.

BioNTech and Pfizer’s coronavirus vaccine may be effective with the new COVID-19 strain. This was announced by BioNTech CEO Ugur Shahin to the DPA agency on Tuesday, December 22.

“We have already tested the vaccine against 20 other variants of the virus with different mutations. The immune response caused by our vaccine has always inactivated all forms of the virus,” Shahin said.

He believes that from a scientific point of view, the probability that the drug will be effective against a new variation of the coronavirus is quite high. At the same time, the company will study the effect of the vaccine in more detail in the near future.

“Now we have to test this experimentally. It will take about two weeks. However, we are confident that this will not significantly affect the mechanism of action.” [препарата]”, – added Shahin.

He noted that BioNTech’s primary goal is to ensure continued vaccine production over the next year. To this end, the company is considering the possibility of creating additional production facilities in addition to its plants in Mainz and Idar-Oberstein (Rhineland-Palatinate), and soon in Marburg (Hesse).

Recall that many countries have suspended passenger flights with the United Kingdom due to a new strain of coronavirus found on the island.

Also, infectious disease doctor Viktor Petrov says that a new strain of coronavirus registered in Britain is already found in Transcarpathia.

In addition, the Ministry of Health gave recommendations due to COVID-19 mutations. Ukrainians are not recommended to visit the UK and other countries where a new strain of coronavirus has been discovered.

News of Correspondent.net on Telegram. Subscribe to our channel https://t.me/korrespondentnet

[ad_2]